Drug
Cc-486 clinical trials
Also written CC-486 and BMS-986345.
- studies test it
- 43
- open now
- 5
- in phase 3
- 6
- first study started
- 2012
Keep track of what changes. Save the cc-486 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- CC-486
- 30
Combined with it in one product
Studies by the year they started
43 studies that test it; most in 2022 (7)
| Year | Studies |
|---|---|
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 23
- Phase 3
- 6
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 24
Celgene (14) · Bristol-Myers Squibb (4) · National Cancer Institute (NCI) (3) · French Innovative Leukemia Organisation (2) · Jonathan Brammer (1) · Groupe Francophone des Myelodysplasies (1) · City of Hope Medical Center (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Venetoclax (3) · Lenalidomide (3) · Duvelisib (3) · Romidepsin (2) · Obinutuzumab (2) · Nivolumab (1) · Dexamethasone (1) · CC-223 (1)
Studies
Open first, then newest update. How each study uses cc-486 is read from its arms, and is right about nine times in ten.
Testing it · 43
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT04803201Written as Oral azacitidine
- Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-InequalityRecruitingPhase 4Virginia Commonwealth UniversityNCT06370000Written as Oral Azacitidine
- Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.Not yet recruitingPhase 2French Innovative Leukemia OrganisationNCT07463768Written as Ivosidenib + oral azacitidine
- CC-486 and Venetoclax for Acute Myeloid LeukemiaRecruitingPhase 1University of Colorado, DenverNCT05287568Written as CC-486
- Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid LeukemiaRecruitingPhase 2French Innovative Leukemia OrganisationNCT06022003Written as AzaCITIDine Oral Tablet
- Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic LeukemiaActive, not recruitingPhase 1/2Jonathan BrammerNCT05141682Written as Oral Azacitidine
- Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedPhase 1National Cancer Institute (NCI)NCT04447027Written as CC-486 (5-azacitidine)
- Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT04799275Written as Oral Azacitidine
- Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCTCompletedPhase 3University of BirminghamNCT04173533Written as Oral azacitidine
- Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic SyndromesActive, not recruitingPhase 1/2Groupe Francophone des MyelodysplasiesNCT05782127Written as Onureg + Venetoclax
- Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedPhase 2CelgeneNCT02546986Written as CC-486
- CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or RelapsedActive, not recruitingPhase 1City of Hope Medical CenterNCT05162976Written as Oral Azacitidine
- Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS PatientsCompletedPhase 2University of FlorenceNCT04806906Written as CC-486
- An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionActive, not recruitingPhase 2Bristol-Myers SquibbNCT05413018Written as CC-486
- Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITLCompletedPhase 3The Lymphoma Academic Research OrganisationNCT03593018Written as Oral azacitidine
- A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersCompletedPhase 2CelgeneNCT02494258Written as CC-486
- A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)Active, not recruitingPhase 2/3Bristol-Myers SquibbNCT05469737Written as Oral Azacitidine
- A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete RemissionActive, not recruitingPhase 2Bristol-Myers SquibbNCT05197426Written as Oral Azacitidine
- A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid MalignanciesTerminatedPhase 1Bristol-Myers SquibbNCT05209295Written as Onureg
- Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05065866Written as BMS-986345
See all 43 studies that test cc-486 →
Given in every arm · 6 — cc-486 is usual care beside what is tested
- A Study of Enhancing Response to MK-3475 in Advanced Colorectal CancerCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02512172Written as Oral CC-486
- Study of Magrolimab Combinations in Participants With Myeloid MalignanciesTerminatedPhase 2Gilead SciencesNCT04778410Written as CC-486
- Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic SyndromesCompletedPhase 2CelgeneNCT02281084Written as Oral Azacitidine
- Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.CompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01928576Written as CC-486 300
- A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid TumorsCompletedPhase 1CelgeneNCT01478685Written as CC-486
- Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous LeukemiaCompletedPhase 1CelgeneNCT00528983Written as Oral Azacitidine
As the comparator · 1 — what is tested is compared with cc-486
Codes
What other systems call cc-486 · ClinicalTrials.gg INT001381
- MeSH (NLM) C000709231cc-486One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709231 | cc-486 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.